CURE Pharmaceutical

70 articles about CURE Pharmaceutical

• Medolife Rx And CURE Pharmaceutical Holding Corp. Collaborate For A Significant Increase Of Revenue

  2/23/2021

  Medolife Rx, Inc., a majority owned subsidiary of Quanta, Inc., announced that Medolife and CURE Pharmaceutical Holding Corp. signed a Collaboration and Joint Development Agreement on February 7, 2021.

• CURE Pharmaceutical to Present at H.C. Wainwright BioConnect 2021 Virtual Conference

  1/7/2021

  CURE Pharmaceutical Holding Corp (“CURE” or the “Company”) (OTC: CURR), a technology-focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the Company’s Chief Executive Officer Rob Davidson will be presenting at the H.C. Wainwright BioConnect 2021 Virtual Conference being held January 11-14. The presentation can be viewed

• CURE Pharmaceutical to Present at LD Micro on December 15, Schedules Investor Video Webcast for December 17

  12/14/2020

  CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTCQB: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, today announced that management will present on the company at the LD Micro Main Event Conference on Tuesday, December 15, 2020 at 11:00 AM Pacific Time. Additionally, the Company will host a video webcast with the investment community on Thu

• CURE Pharmaceutical Issues Letter to Shareholders

  11/18/2020

  CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today that it has issued a letter to its shareholders providing commentary on the Company’s recent announcements and upcoming plans. Highlights of the letter include: The Company’s efforts to further position itself as an

• CURE Pharmaceutical’s® Wholly Owned Subsidiary SeraLabs® Introduces Nutri-Strips™, a Revolutionary Oral Thin Film Strip Technology

  10/29/2020

  SeraLabs Challenges the Status Quo of the Health & Wellness Sector with Nutri-Strips for commercialization and monetization with the launch of first product, Sleep A.S.A.P.

• CURE Pharmaceutical Completes $20 Million Acquisition of Sera Labs, a Leading Health, Wellness and Beauty Brand Marketing and Multi-Channel Distribution Platform Company

  9/24/2020

  CURE Pharmaceutical Holdings (OTC: CURR) today announced its definitive agreement to acquire Sera Labs, Inc. The closing is anticipated to occur in early October. As previously announced, the transaction consists of an up-front payment of $20 million, of which $1 million was paid in cash and $19 million has been allocated in CURE stock at a valuat

• CURE Pharmaceutical to Present at Two Virtual Events in September

  9/2/2020

  - CURE will present at the LD 500 Virtual Conference, September 4 at 8:20 am PDT -  - CURE CEO will be a panelist at the 4@4 Forum on September 10 @4pm PDT - OXNARD, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it will be presenting at two upcoming virtual conferences in September. The LD 500 Virtual Conference on Friday, September 4 at 8:20amPDT/11:20pm EDT Rob Davidson, Preside

• CURE Pharmaceutical to Acquire Sera Labs, a Leader in the CBD Industry with Proprietary Products and Multi-Channel Distribution Platform, in a $20 Million Transaction

  7/28/2020

  MOU to acquire 100% of privately held Sera Labs for $20 million, which consists primarily of stock with key earn out considerations totaling up to an additional $20 million within two years of completing the acquisition.   Sera Labs brings to CURE a high-margin, retail and direct-to-consumer business with accelerating sales of its more than 20 products in the health & wellness, beauty, and pets categories and strong traction in both e-commerce and wholesale-to-retail distribution with to

• CURE Pharmaceutical CBD Oral Thin Film Pharmacokinetic Study Shows Improved Bioavailability Compared to CBD Soft Gel Significantly higher serum concentration and absorption Showcases CUREform™ encapsulation and oral thin film technology

  7/15/2020

  CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that its 25mg cannabidiol (CBD) oral thin film (OTF) showed improved bioavailability of cannabidiol in healthy subjects, compared with 25mg soft gels. Specifically, a pharmacokinetic (PK) study in 14 healthy adults showed a significantly higher serum concentration (Cmax) and significantly faster absorption (Tmax) from CURE's CBD OTF dose form t

• CURE Pharmaceutical Receives NSF’s cGMP Certification for Dietary Supplements

  7/8/2020

  CURE Pharmaceutical, (OTC: CURR), an innovative drug delivery and development company, today announced that its 25,000 square foot manufacturing facility has earned NSF International, cGMP certification for the manufacture of dietary supplements. This certification is issued only after extensive material and facility analysis and gives suppliers, retailers, regulators and consumers assurance that products manufactured by CURE meet the highest s

• CURE Pharmaceutical Appoints Chief Business Officer- Jonathan Berlent Appointed to Newly Created Role -

  6/16/2020

  CURE Pharmaceutical, (OTC: CURR), an innovative drug delivery and development company, today named Jonathan Berlent, 51, to the newly created position of Chief Business Officer. Mr. Berlent will be responsible for corporate strategy, sourcing and executing business development opportunities and will serve as a member of the company’s Executive Management Committee. He will report to Rob Davidson, CURE Pharmaceutical’s Chief Executive Officer.

• CURE Pharmaceutical Announces Exercise of Warrants for Cash Proceeds of Approximately $1.4 Million and Completes Earn Out Related to 2019 Acquisition

  6/9/2020

  CURE Pharmaceutical Holding Corp. (OTC: CURR), an innovative drug delivery company that is developing novel ways to deliver active ingredients, announced today that it strengthened its balance sheet with the receipt of $1.4 million in cash from the exercise of warrants to purchase 708,467 shares of CURE’s common stock held by certain stockholders of Chemistry Holdings, Inc. (Chemistry Holdings) at a reduced exercise price of $2.00 per share (

• CURE Pharmaceutical [OTCQB:CURR] Expands to Mexico in Collaboration with Factoria Bogar SubsidiaryCURE extends vitamin D, sleep and combination CBD products distribution throughout Mexico

  6/3/2020

  CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announced today a collaboration with PMI, a subsidiary of Factoria Bogar in Guadalajara, Mexico.

• CURE Pharmaceutical [OTCQB:CURR] Secures Chinese Patent on its Oral Thin Films to Treat Erectile DysfunctionED Drug Market Expected to Reach US$6.5B by 2025

  3/17/2020

  CURE Pharmaceutical, an innovative drug delivery and development company, announced the allowance of Chinese Patent No. ZL201480039313.6.

• CURE Pharmaceutical [OTCQB:CURR] Licenses Cannabis Extraction Patents to Vanguard ScientificVanguard Scientific builds customer trust with CUREinside™ patented methods

  2/12/2020

  CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced a licensing and collaboration agreement with Vanguard Scientific Systems, Inc., a premier provider of equipment, systems and performance solutions servicing the botanical extraction industry, including both the MIDAS XII, a next-generation GMP compliant supercritical CO2 extraction technology, as well as industrially scaled CO2 facility solutions.

• UPDATE – CURE Pharmaceutical [OTCQB:CURR] Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery

  2/5/2020

  CURE debuts “CUREinside” quality mark on the packaging of ReLeaf Europe’s sublingual tinctures and new topical cream product lines

• CURE Pharmaceutical [OTCQB:CURR] Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery

  2/5/2020

  CURE debuts “CUREinside” quality mark on the packaging of ReLeaf Europe’s sublingual tinctures and new topical cream product lines

• CURE Pharmaceutical [OTCQB:CURR] to Present at the 12th Annual LD Micro Main Event Investor ConferenceCURE CEO to discuss company’s expanded technology platform and pharmaceutical pipeline

  12/5/2019

  CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it will be presenting at the 12th Annual LD Micro Main Event on Wednesday, December 11 at 9:45 AM PST/ 12:45 PM ET at the Luxe Sunset Boulevard Hotel in Los Angeles

• CURE Pharmaceutical [OTC: CURR] Names Canopy Rivers’ Chairman, John K. Bell, To Board of DirectorsIndustry veteran brings 40 year of experience to support CURE’s rapid growth

  11/19/2019

  CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it has named John K. Bell, FCA, FCPA, ICD.D to its board of directors

• CURE Pharmaceutical [OTCQB:CURR] Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension

  11/14/2019

  CURE Pharmaceutical announced that it purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development and commercialization of branded 505 pharmaceutical products.